Source: Medical Buyer

Profectus Biosciences: Aurobindo Gains On Plans To Acquire Business Assets From Profectus

Aurobindo Pharma advanced 1.87% to Rs 458.60 after the company informed that its US-based subsidiary has entered into an agreement to acquire certain business assets from Profectus BioSciences Inc., USA....Read More

Read full article »
Profectus Biosciences's Competitors | Profectus Biosciences's News | Profectus Biosciences's Financials
Stay up-to-date with the latest news on Profectus Biosciences
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Jeffrey N. Meshulam's photo - President of Profectus Biosciences

President

Jeffrey N. Meshulam

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on Profectus Biosciences